Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

1(20%)

Results Posted

300%(3 trials)

Terminated

3(60%)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

completed120%

recruiting120%

terminated360%

Recent Activity

1 active trials

Showing 5 of 5

completedphase_1

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NCT05075603

terminatedphase_2

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

NCT04984811

recruitingphase_2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

NCT05465954

terminatedphase_1

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

NCT04588038

terminatedphase_1

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

NCT04893018

Clinical Trials (5)

Showing 5 of 5 trials

NCT05075603Phase 1

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Completed

NCT04984811Phase 2

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Terminated

NCT05465954Phase 2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recruiting

NCT04588038Phase 1

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Terminated

NCT04893018Phase 1

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5